To test the role of Src-Y216GSK-3 axis in prostate cancer, we first performed in vitro studies using PC3 cells treated with dasatinib alone or in combination with docetaxel as therapeutic agents and subjected those to different sets of experiments to establish their effects on tumorigenic and metastatic status. This evidence concerns the gene SRC and prostate cancer.